Immune microenvironment in colorectal cancer: A new hallmark to change old paradigms

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  De La Cruz Merino, Luis ^a   Henao Carrasco, Fernando ^a   Vicente Baz, David ^a   Nogales Fernández, Esteban ^a   Reina Zoilo, Juan José ^a   Codes Manuel De Villena, Manuel ^a   Pulido, Enrique Grande ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45RO ANTIGEN; CD56 ANTIGEN; CD57 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; KI 67 ANTIGEN; OXALIPLATIN; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; B7 ANTIGEN; TUMOR MARKER;

ANTIGEN PRESENTING CELL; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LYMPHOCYTIC INFILTRATION; MEMORY CELL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CARCINOMA; COLORECTAL TUMOR; IMMUNOLOGY; METABOLISM; MICROSATELLITE INSTABILITY;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; CTLA-4 ANTIGEN; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSATELLITE INSTABILITY; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84855569707     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/174149     Document Type: Review

References (61)

1. Abbas A. K., Lichtman A. H., Pillai S., Abbas A. K., Lichtman A. H., Pillai S., Immunity to tumors Cellular and Molecular Immunology 2007 Philadelphia, Pa, USA Saunders Elsevier 397 417
2. Boyle P., Ferlay J., Cancer incidence and mortality in Europe, 2004 Annals of Oncology 2005 16 3 481 488 (Pubitemid 40458328)
3. Parkin D. M., Bray F., Ferlay J., Pisani P., Global cancer statistics, 2002 Ca-A Cancer Journal for Clinicians 2005 55 2 74 108 (Pubitemid 40372904)
4. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H., CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer Cancer Research 1998 58 16 3491 3494 (Pubitemid 28376536)
5. Swann J. B., Smyth M. J., Immune surveillance of tumors Journal of Clinical Investigation 2007 117 5 1137 1146 (Pubitemid 46718398)
6. Hanahan D., Weinberg R. A., Hallmarks of cancer Cell 2011 144 5 646 674
7. De La Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., De Villena M. E. C. M., Cancer and immune response: old and new evidence for future challenges Oncologist 2008 13 12 1246 1254
8. Nishikawa H., Sakaguchi S., Regulatory T cells in tumor immunity International Journal of Cancer 2010 127 4 759 767
9. Vignali D. A. A., Collison L. W., Workman C. J., How regulatory T cells work Nature Reviews Immunology 2008 8 7 523 532
10. Zou W., Regulatory T cells, tumour immunity and immunotherapy Nature Reviews Immunology 2006 6 4 295 307
11. Jiang H., Chess L., Regulation of immune responses by T cells New England Journal of Medicine 2006 354 11 1116 1176
12. Langer L. F., Clay T. M., Morse M. A., Update on anti-CTLA-4 antibodies in clinical trials Expert Opinion on Biological Therapy 2007 7 8 1245 1256 (Pubitemid 47305249)
13. Leach D. R., Krummel M. F., Allison J. P., Enhancement of antitumor immunity by CTLA-4 blockade Science 1996 271 5256 1734 1736 (Pubitemid 26102823)
14. Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8372 8377 (Pubitemid 36842552)
15. Demaria S., Kawashima N., Yang A. M., Devitt M. L., Babb J. S., Allison J. P., Formenti S. C., Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer Clinical Cancer Research 2005 11 2 I 728 734 (Pubitemid 40116901)
16. Khan S., Burt D. J., Ralph C., Thistlethwaite F. C., Hawkins R. E., Elkord E., Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells Clinical Immunology 2010 138 85 96
17. Callahan M. K., Wolchok J. D., Allison J. P., AntiCTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy Seminars in Oncology 2010 37 5 473 484
18. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma New England Journal of Medicine 2010 363 8 711 723
19. Tarhini A. A., Iqbal F., CTLA-4 blockade: therapeutic potential in cancer treatments OncoTargets and Therapy 2010 3 15 25
20. Jass J. R., Love S. B., Northover J. M. A., A new prognostic classification of rectal cancer Lancet 1987 1 8545 1303 1306 (Pubitemid 17072200)
21. Ropponen K. M., Eskelinen M. J., Lipponen P. K., Alhava E., Kosma V. M., Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer Journal of Pathology 1997 182 3 318 324 (Pubitemid 27285785)
22. Pihl E., Nairn R. C., Milne B. J., Lymphoid hyperplasia: a major prognostic feature in 519 cases of colorectal carcinoma American Journal of Pathology 1980 100 2 469 480 (Pubitemid 10037088)
23. Menon A. G., Janssen-Van Rhijn C. M., Morreau H., Putter H., Tollenaar R. A. E. M., Van De Velde C. J. H., Fleuren G. J., Kuppen P. J. K., Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis Laboratory Investigation 2004 84 4 493 501 (Pubitemid 41656477)
24. Jochems C., Schlom J., Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity Experimental Biology and Medicine 2011 236 5 567 579
25. Fontenot J. D., Gavin M. A., Rudensky A. Y., Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nature Immunology 2003 4 4 330 336 (Pubitemid 36432314)
26. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3 Science 2003 299 5609 1057 1061 (Pubitemid 36222930)
27. Gavin M. A., Rasmussen J. P., Fontenot J. D., Vasta V., Manganiello V. C., Beavo J. A., Rudensky A. Y., Foxp3-dependent programme of regulatory T-cell differentiation Nature 2007 445 7129 771 775 (Pubitemid 46279714)
28. Zheng Y., Josefowicz S. Z., Kas A., Chu T. T., Gavin M. A., Rudensky A. Y., Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells Nature 2007 445 7130 936 940
29. lvaro T., De La Cruz-Merino L., Henao-Carrasco F., Villar Rodrguez J. L., Vicente Baz D., Codes Manuel De Villena M., Provencio M., Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes Journal of Biomedicine and Biotechnology 2010 2010
30. Ladoire S., Martin F., Ghiringhelli F., Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer Cancer Immunology, Immunotherapy 2011 60 7 909 918
31. Salama P., Phillips M., Grieu F., Morris M., Zeps N., Joseph D., Platell C., Iacopetta B., Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer Journal of Clinical Oncology 2009 27 2 186 192
32. Correale P., Rotundo M. S., Del Vecchio M. T., Remondo C., Migali C., Ginanneschi C., Tsang K. Y., Licchetta A., Mannucci S., Loiacono L., Tassone P., Francini G., Tagliaferri P., Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy Journal of Immunotherapy 2010 33 4 435 441
33. Frey D. M., Droeser R. A., Viehl C. T., Zlobec I., Lugli A., Zingg U., Oertli D., Kettelhack C., Terracciano L., Tornillo L., High frequency of tumor-infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients International Journal of Cancer 2010 126 11 2635 2643
34. Nosho K., Baba Y., Tanaka N., Shima K., Hayashi M., Meyerhardt J. A., Giovannucci E., Dranoff G., Fuchs C. S., Ogino S., Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review Journal of Pathology 2010 222 4 350 366
35. Sinicrope F. A., Rego R. L., Ansell S. M., Knutson K. L., Foster N. R., Sargent D. J., Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma Gastroenterology 2009 137 4 1270 1279
36. Camus M., Tosolini M., Mlecnik B., Pages F., Kirilovsky A., Berger A., Costes A., Bindea G., Charoentong P., Bruneval P., Trajanoski Z., Fridman W. H., Galon J., Coordination of intratumoral immune reaction and human colorectal cancer recurrence Cancer Research 2009 69 6 2685 2693
37. Diederichsen A. C., Hjelmborg J. B., Christensen P. B., Zeuthen J., Fenger C., Prognostic value of the CD4+/CD8+ ratio of tumor infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumor cells Cancer Immunology, Immunotherapy 2003 52 423 428 (Pubitemid 36831363)
38. Chiba T., Ohtani H., Mizoi T., Naito Y., Sato E., Nagura H., Ohuchi A., Ohuchi K., Shiiba K., Kurokawa Y., Satomi S., Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis British Journal of Cancer 2004 91 9 1711 1717 (Pubitemid 39546145)
39. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pags C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Pags F., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 2006 313 5795 1960 1964 (Pubitemid 44498003)
40. Pags F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., Mlecnik B., Kirilovsky A., Nilsson M., Damotte D., Meatchi T., Bruneval P., Cugnenc P. H., Trajanoski Z., Fridman W. H., Galon J., Effector memory T cells, early metastasis, and survival in colorectal cancer New England Journal of Medicine 2005 353 25 2654 2666 (Pubitemid 41817714)
41. Guidoboni M., Gaf R., Viel A., Doglioni C., Russo A., Santini A., Del Tin L., Macr E., Lanza G., Boiocchi M., Dolcetti R., Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis American Journal of Pathology 2001 159 1 297 304 (Pubitemid 33704214)
42. Ogino S., Nosho K., Irahara N., Meyerhardt J. A., Baba Y., Shima K., Glickman J. N., Ferrone C. R., Mino-Kenudson M., Tanaka N., Dranoff G., Giovannucci E. L., Fuchs C. S., Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype Clinical Cancer Research 2009 15 20 6412 6420
43. Pags F., Kirilovsky A., Mlecnik B., Asslaber M., Tosolini M., Bindea G., Lagorce C., Wind P., Marliot F., Bruneval P., Zatloukal K., Trajanoski Z., Berger A., Fridman W. H., Galon J., In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer Journal of Clinical Oncology 2009 27 35 5944 5951
44. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W. -H., Pags F., Galon J., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction Journal of Clinical Oncology 2011 29 6 610 618
45. Dolcetti R., Viel A., Doglioni C., Russo A., Guidoboni M., Capozzi E., Vecchiato N., Macri E., Fornasarig M., Boiocchi M., High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability American Journal of Pathology 1999 154 6 1805 1813 (Pubitemid 29262862)
46. Ishikawa T., Fujita T., Suzuki Y., Okabe S., Yuasa Y., Iwai T., Kawakami Y., Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability Cancer Research 2003 63 17 5564 5572 (Pubitemid 37139879)
47. Michel S., Benner A., Tariverdian M., Wentzensen N., Hoefler P., Pommerencke T., Grabe N., Von Knebel Doeberitz M., Kloor M., High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability British Journal of Cancer 2008 99 11 1867 1873
48. Suzuki A., Masuda A., Nagata H., Mature dendritic cells make clusters with T cells in the invasive margin of colorectal carcinoma Journal of Pathology 2002 196 1 37 43
49. Dadabayev A. R., Sandel M. H., Menon A. G., Morreau H., Melief C. J.M., Offringa R., Van Der Burg S. H., Rhijn C. J.-V., Ensink N. G., Tollenaar R. A.E.M., Van De Velde C. J.H., Kuppen P. J.K., Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells Cancer Immunology, Immunotherapy 2004 53 11 978 986 (Pubitemid 39371742)
50. Mizoi T., Ohtani H., Suzuki Y., Shiiba K., Matsuno S., Nagura H., Intercellular adhesion molecule-1 expression by macrophages in human gastrointestinal carcinoma: possible roles as host immune/inflammatory reaction Pathology International 1995 45 8 565 572
51. Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G., The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 2008 118 6 1991 2001 (Pubitemid 351872317)
52. Obeid M., Tesniere A., Ghiringhelli F., Fimia G. M., Apetoh L., Perfettini J. L., Castedo M., Mignot G., Panaretakis T., Casares N., Métivier D., Larochette N., Van Endert P., Ciccosanti F., Piacentini M., Zitvogel L., Kroemer G., Calreticulin exposure dictates the immunogenicity of cancer cell death Nature Medicine 2007 13 1 54 61 (Pubitemid 46067386)
53. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J. P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nature Medicine 2007 13 9 1050 1059 (Pubitemid 47517504)
54. Obeid M., Tesniere A., Panaretakis T., Tufi R., Joza N., Van Endert P., Ghiringhelli F., Apetoh L., Chaput N., Flament C., Ullrich E., De Botton S., Zitvogel L., Kroemer G., Ecto-calreticulin in immunogenic chemotherapy Immunological Reviews 2007 220 1 22 34 (Pubitemid 350045569)
55. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapya practical partnership Nature Reviews Cancer 2005 5 5 397 405
56. Gasser S., Orsulic S., Brown E. J., Raulet D. H., The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 2005 436 7054 1186 1190 (Pubitemid 41232299)
57. Lake R. A., Van Der Most R. G., A better way for a cancer cell to die New England Journal of Medicine 2006 354 23 2503 2504 (Pubitemid 43855057)
58. Zitvogel L., Kepp O., Senovilla L., Menger L., Chaput N., Kroemer G., Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway Clinical Cancer Research 2010 16 12 3100 3104
59. Tesniere A., Schlemmer F., Boige V., Kepp O., Martins I., Ghiringhelli F., Aymeric L., Michaud M., Apetoh L., Barault L., Mendiboure J., Pignon J. P., Jooste V., Van Endert P., Ducreux M., Zitvogel L., Piard F., Kroemer G., Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 2010 29 4 482 491
60. Haynes N. M., van der Most R. G., Lake R. A., Smyth M. J., Immunogenic anti-cancer chemotherapy as an emerging concept Current Opinion in Immunology 2008 20 5 545 557
61. Waller E. K., The role of sargramostim (rhGM-CSF) as immunotherapy Oncologist 2007 12 2, supplement 2 22 26